CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Mature T-cell neoplasms represent approximately 10% of non-Hodgkin lymphomas.
• These neoplasms are characterized by aggressive clinical behavior, poor therapeutic response, and reduced survival rates.
• The CD20 antigen is traditionally recognized as a specific marker for B-cell lineage, crucial for differentiating T-cell from B-cell neoplasms.

Observation:

• This report details two cases of a rare T-cell leukemia/lymphoma subset.
• Both cases exhibited a unique immunophenotype, notably expressing the CD20 antigen.
• This observation challenges the established understanding of CD20 as exclusively a B-cell marker.

Findings:

• The study identified a rare subset of T-cell neoplasms expressing the CD20 antigen.
• This finding suggests that CD20 expression is not exclusive to B-cell lineage.
• The immunophenotypic profile of these T-cell neoplasms is distinct.

Implications:

• The presence of CD20 in T-cell lymphomas warrants further investigation into its significance.
• CD20 expression in T-cell neoplasms may enable treatment with anti-CD20 monoclonal antibodies, such as rituximab.
• This discovery could lead to novel therapeutic strategies for aggressive T-cell malignancies.